Economic status, a salient motivator for medicalisation of FGM in sub-Saharan Africa: Myth or reality from 13 national demographic health surveys

Imran O. Morhason-Bello a, b, d, *, Adeniyi Francis Fagbamigbe c, Yusuf Olushola Kareem b, c, Oladosu A. Ojengbede d

a Department of Obstetrics and Gynaecology, Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria
b Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria
c Department of Epidemiology and Medical Sciences, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria
d Centre for Population and Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Nigeria

ARTICLE INFO

Keywords:
Sub-Saharan Africa
FGM medicalisation
Socio-economic status
DHS surveys
Multi-level modelling
Health workers

ABSTRACT

Female Genital Mutilation or Cutting (FGM) and its medicalisation remain a challenge in sub-Saharan African (SSA). Early identification of at-risk women might help in instituting focused counselling against FGM medicalisation. We hypothesised that the risk of medicalised FGM by girls/women is associated with socioeconomic status (SES) their household belongs.

We used 2010–2019 Demographic and Health surveys data from 13 countries in SSA. We analysed information on 214,707 women (Level 1) nested within 7299 neighbourhoods (Level 2) from the 13 countries (Level 3). We fitted 5 multivariable binomial multilevel logistic regression models using the MLWin 3.03 module in Stata. The estimation algorithms adopted was the first order marginal quasi-likelihood linearisation using the iterative generalised least squares.

The odds of FGM medicalisation increased with the wealth status of the household of the woman, with 29%, 45%- and 75%-times higher odds in the middle, richer and richest household wealth quintiles, respectively than those from the poorest households (p < 0.05). The more educated a woman and the better a woman’s community SES was, the higher her odds of reporting medicalisation of FGM. Rural community was associated with higher odds of medicalised FGM than urban settings.

Medicalised FGM is common among women from a high socioeconomic, educational background and rural settings of SSA. We recommend a culturally sensitive policy that will discourage perpetuation of FGM, particularly by healthcare providers. Future studies should focus on identifying drivers of FGM among the high social class families in the society in SSA.

Introduction

Female genital mutilation or cutting (FGM) was initially regarded as a public health challenge of low-middle income countries, driven largely by socio-cultural and religious beliefs (McCauley & van den Broek, 2019; Nabaneh & Muula, 2019; Odukogbe, Afolabi, Bello, & Adeyianju, 2017). However, FGM practice has spread to high-income countries over the years due to increasing migration of the population of people that believe, promote and practice FGM (Karlsen, Mogilnicka, Carver, & Pantazis, 2019) (Creighton, Samuel, Otoo-Oyortey, & Hodes, 2019).

According to the World Health Organisation (WHO), FGM are procedures that involve partial or total removal of any part of the external female genital organ for non-medical reasons. FGM practice is classified into four different types based on the extent of anatomic disruption of external genital organs of girls and women (Odukogbe et al., 2017). The structural damage to the female genital organ could be in form of an excision, piercing, scraping, pricking, incising or cauterisation of skin (Odukogbe et al., 2017).

FGM is most common in Africa, Middle East, and some part of Asia, as part of socio-cultural practice or rite of passage to maturity for girls...
and women (Cappa, Van Baalen, & Leye, 2019; Odukogbe et al., 2017; Yoder, Wang, & Johansen, 2013). It is estimated that 200 million girls and women are living with FGM in over 30 countries (Utz-Billing & Kentenich, 2008; Yoder et al., 2013). Each year, an additional 3.6 million girls/women are at risk of FGM if there is no intervention to stop it (Cappa et al., 2019; Utz-Billing & Kentenich, 2008). In Africa, about 90 million girls/women had FGM, and a significant number of these women (one in nine) are likely to be exposed to another cutting when they need medical intervention in future (Cappa et al., 2019) (Utz-Billing & Kentenich, 2008; Yoder et al., 2013). Victims of FGM suffer health, emotional or and psychological trauma (Odukogbe et al., 2017; Utz-Billing & Kentenich, 2008). The common adverse consequences include bleeding, infections, chronic pains, infertility, obstetric complications, post-traumatic stress disorders, depression, lack of self-esteem, guilty feelings and sexual dysfunction (Farage, Miller et al., 2015; Klein, Helzner, Shayowitz, Kohlhoff, & Smith-Norowitz, 2018; Pycha, Pycha et al., 2018; Sigurjonsson & Jardal, 2018).

Involvement of health workers in the practice of FGM is one of the early interventions that was put forward to reduce harm to girls and women (Utz-Billing & Kentenich, 2008). This strategy was initially a “stop-gap measure” to ensure respect for cultural and religious beliefs and reduction of harm associated with FGM (Bazi, 2017; Kimani & Shell-Duncan, 2018; Nabaneh & Muula, 2019). Medicalisation of FGM was introduced with legislative support and issuance of a tacit supportive statement by some professional organization, or by religious leaders. In some countries such as Somalia and Sudan, health workers were trained on how to perform FGM to minimise harm (Leye, Van Eckert, Shamu, Esho, & Barrett, 2019). However, the United Nations, human right organisations, civil societies and professional organisations rejected medicalisation of FGM (Leye et al., 2019). Specifically, the UN General Assembly passed a resolution in 2012 by declaring FGM as a violation of the human right and further pronounced that all member countries should prioritize and take action towards total eradication/elimination/abandonment of FGM practice including medicalisation (United Nations, 2012; World Health Organisation, 2012).

Research evidence showed that medicalisation agenda of FGM has not reduced the burden and complication appreciably. Although some Nigerian studies showed a reduced rate of complications from FGM performed by health workers, studies from Asia did not show any significant difference between health workers and traditional circumcisers (Obianwu 2018; Onuh et al., 2006). While efforts are being made to discourage FGM practice especially among healthcare workers through legislation and campaigns, health workers are still actively involved in this practice as part of their clinical service (Leye et al., 2019).

Studies from national surveys showed that medicalised FGMs are common in SSA, Middle East and part of Asia (Kimani & Shell-Duncan, 2018; Leye et al., 2019). Worldwide, an estimated 16 million women reportedly (26% of the total burden) procured FGM from healthcare workers, and the majority of these women live in SSA (Kimani & Shell-Duncan, 2018). After the 2012 push back by the United Nations Assembly and her member states against FGM, medicalised FGM is still being reported in several national surveys and individual-level studies in SSA (McCauley & van den Broek, 2019). Some studies showed that continuous involvement of healthcare workers in offering FGM to clients might be due to their belief in such practice, respect for the culture of people in the community, and fear that their clients might consult traditional local circumcisers (Kimani, Esho et al., 2018; Kimani & Shell-Duncan, 2018; Obianwu 2018).

A systematic review in 2017 showed that financial inducement of healthcare workers by people requesting FGM might be one of the key driving motivations for increasing medicalisation of FGM, aside from other factors mentioned in previous studies (Doucet, Palliot, & Groleau, 2017; Serrour, 2013). However, we are not aware of any study that primarily investigated household wealth across countries as an independent risk factor for the medicalisation of FGM in SSA. Early identification of at-risk family in the community might help in instituting early and focused counselling against tempting healthcare workers with money to perform FGM for them. This will help policymakers and experts to develop focused support/intervention to minimise medicalised FGM. Specifically, we hypothesised that the risk of having medicalised FGM by girls and women is associated with the socio-economic status their household belongs.

**Methods**

**Data source**

We used the most recent data collected from Demographic and Health surveys conducted between 2010 and 2019 in SSA countries. A major inclusion criterion is that FGM-related data must have been collected in the surveys held between 2010 and 2019 in SSA and available as of December 2019. We examined all DHS data conducted between 2010 and 2019 and identified only 13 countries with information on FGM/C. In all, 13 countries: Burkina-Faso, Cote d’Ivoire, Ethiopia, Gambia, Guinea, Kenya, Mali, Niger, Nigeria, Senegal, Sierra Leone, Tanzania, and Togo were included in this study. Furthermore, we excluded Senegal and Niger from all analysis on medicalisation of FGM because they had zero prevalence. DHS data are cross-sectional, nationally representative and routinely collected in low and middle-income countries across the world. The details of the year of survey and the number of women who participated in the study and the prevalence of FGM and FGM medicalisation are shown in Table 1.

**Sampling**

All DHS surveys use multistage cluster probability sampling methods to select eligible respondents in each of the countries. The surveys are conducted by trained interviewers using similarly structured questionnaires. The surveys use a set of standardised questions to assess women sexual and reproductive history, attitudes, knowledge and practices and relevant background characteristics.

**Measurement of variables**

**Outcome variable**

The primary outcome variable of this study was the medicalisation of FGM. It is a binary outcome extracted from a set of questions. Firstly, all respondents were asked if they have ever had FGM. Those who answered in the affirmative were then asked who performed the cutting. The responses varied from a health professional: doctor, trained nurse/traditional birth attendant, other traditional. Those who had their FGM performed by health professionals were classified as those who had medicalisation of FGM.

**Explanatory variables**

The explanatory variables are categorised into three levels: individual, neighbourhood and country levels as shown in Fig. 1.

**Individual-level factors**

The following individual-level factors were included in the models: age (15–19, 20 to 24, 25 to 34 and 35 or older), employment status (working or not working), education (no education, primary or secondary or higher), and wealth index (poorest, poorer, middle, richer and richest), age at first marriage (never, <15, 15 to 19 and 20 years or older) and marital status (currently, formerly and never married).

**Neighbourhood-level factors**

We used the term “neighbourhood” to describe clustering within the same geographical living environment based on the primary sample unit (PSU) within the DHS data. The neighbourhood-level factors included in this study are a place of residence (rural or urban) and the socio-
economic status of the neighbourhoods as a proxy for the neighbourhood socioeconomic (SES) disadvantage. The SES was operationalized with a principal component comprised of the proportion of respondents with no formal education, unemployed, household wealth quintile (asset index below 20% poorest quintile). A standardized score with mean 0 and standard deviation 1 was generated and categorised into 5: 1 (highest) to 5 (lowest).

Country-level factors

We retrieved the country-level variables from the human index reports published by the United Nations database (United Nations, 2018; United Nations Development Programme, 2018). We extracted countries’ percentage rural population (United Nations, 2018), and the intensity of deprivation, both a measure of human development index (HDI) (United Nations, 2018; United Nations Development Programme, 2018). Each of the two country-level factors was then categorised into two (low and high) levels as shown in Fig. 2.

Data analysis

Besides the descriptive statistics to show the prevalence of, and the medicalisation of FGM, we used the multivariable multilevel logistic regression models to identify the contribution of the individual, community and country-level factors associated with the medicalisation of FGM. Senegal and Niger were excluded from the multilevel analysis as they have zero prevalence of medicalisation of FGM. Also, women who have not been circumcised were excluded from further analysis.

We fitted five multilevel binary logistic regression models as shown in Table 3. The first model was the null model (Model I) to assess the variation due to the neighbourhood- and country-specific random effects without any explanatory variable. The second model (Model II)
included only the individual-level variables conditional on the neighbourhood and country-specific random effects. The third model (Model III) included only the neighbourhood level variables conditional on the neighbourhood and country-specific random effects. The fourth model (Model IV) examines the country-level variables conditional on the neighbourhood and country-specific random effects, while the final model (Model V) estimates the odds of individual, neighbourhood and country-level variables conditional on the neighbourhood and country-specific random effects.

The Binomial logit response models were fitted using the MLWin 3.03 module in Stata. The estimation algorithms adopted was the first order marginal quasi-likelihood linearisation (MQL1) using the iterative generalised least squares (IGLS). Multicollinearity was checked using correlation matrix and variance inflation factor (VIF), as a diagnostic approach to omit some of the correlated variables (Tu, Kellett, Clerehugh, & Gilthorpe, 2005). Age at first sex was dropped in the models. The model deviance computed from the -2loglikelihood was used to evaluate how well the different models considered in this study fitted the data. A lower deviance value indicates a better fit of the model.

**Fixed effects (measures of association)**

The outcomes of the fixed results were reported as odds ratios (ORs) with their 95% confidence intervals (95% CI).

**Random effects (measures of variation)**

We explored the measures of variations using the variance partition component and median odds ratio (MOR). Adopting the methods recommended by Larsen et al. on neighbourhood effects and reported the random effects in terms of the odds (Larsen & Merlo, 2005). The MORs are the measures of the variance of the odds ratio in higher levels (neighbourhood or country) and it is the median value of the odds ratio between neighbourhoods and countries with higher risk and lower risk of medicalised FGM that can be attributed to any of the neighbourhood and country factors (Larsen & Merlo, 2005). A MOR of 1 is an indication that there is no increased risk in medicalised FGM between neighbourhoods or countries. The higher the MOR, the more significant is the risk of medicalised FGM when one move to another neighbourhood or country with a higher propensity for medicalisation. Earlier studies had used a similar approach (Uthman, Ekstrom, & Moradi, 2016; Uthman, Sambala et al., 2018).

**Ethical clearance**

The data originator (ICF macro and population commission of each country) had obtained ethical clearance to conduct these surveys. Prior to each interview, participants gave informed consent to participate in the survey. DHS Program is consistent with the standards for ensuring the protection of respondents’ privacy. The full details can be found at http://dhsprogram.com.

**Results**

The countries, year of data collection, number of women and the weighted prevalence of FGM and the prevalence of FGM medicalisation are listed in Table 1. A total of 13 SSA was included. We analysed information on 214,707 women (Level 1) nested within 7299 neighbourhoods (Level 2) from 13 SSA countries (Level 3) for the univariate and 66,277 women (Level 1) nested within 5075 neighbourhoods (Level 2) from 11 SSA countries excluding Senegal and Niger (Level 3) for the

**Fig. 2. Prevalence of FGM Medicalisation in sub-Saharan Countries.**
multivariable analysis. In Table 1 Sierra Leone and Guinea with FGM prevalence of 90% had less than 1% medicalisation. Nigeria had 40% and Kenya had 22% FGM prevalence but had around 9% and 15% FGM medicalisation, respectively (Fig. 2).

The descriptive statistics on background characteristics, prevalence and medicalisation of FGM were presented in Table 2. More than half (56.2%) of women aged 35–49 years had FGM, while 46.6% of FGM were among 15 to 19-year-old women. The overall mean (95% CI) age at medicalisation was 6.7(6.5–6.9), lowest (2.2(1.7–2.7) years) among Nigerian women and highest among Tanzanian (13.2(10.8–15.6) years) and Malian (13.4(12.6–14.2) years) women (Table 1). The prevalence of FGM increased with age while medicalisation decreased with age. Medicalisation was higher among women who had never gotten married (8.8%) and among women who had their first marriage after attaining 20 years of age (4.7%) compared to women who had their first marriage between ages 15–19 years (2.5%) and before age 15 (2.4%). FGM was higher among women who had no formal education (66.5%), but FGM medicalisation increased with the level of education.

The prevalence was 17.4% among women who had tertiary education, 8.3% among women who had secondary education, 4.6% among primary school holders and 2.0% among women who had no education. The prevalence of medicalisation increased with wealth; the prevalence among women from the families with the richest quintile was 8.6% while those from the poorest wealth quintile families was 1.5%. Medicalisation increases with community socio-economic status, women in the highest community SES had a prevalence of 10.3% compared to 1.2% in the communities with the lowest SES. On the country-level, almost two thirds (60.4%) of women in countries with high intensity of deprivation have had FGM compared with 21.7% in countries with low intensity of deprivation but the reverse was the case for the medicalisation with 3.9% versus 15.1% respectively. Medicalisation was higher among women in countries with a high rural population (5.3%) compared with those with a low rural population (0.3%).

We explored five different and distinct models: (i) null model without any determinant variables (ii) only the individual-level factors (iii) only the neighbourhood-level factors, (iv) only the country-level factors and (v) full model which included all individual-, neighbourhood- and country-level factors at the same time.

In the null model, the percentage total variation attributable to variation between countries is 19.5% (95% CI: 3.6 to 30.2) and a median odds ratio of 3.9 (95% CI: 1.7 to 6.5). Similarly, a high percentage of total variation due to variation between neighbourhood was observed (VPC = 68.9; 95% CI: 61.3 to 74.9) and a median odds ratio (MOR = 10.1; 95% CI: 9.2 to 10.8).

Model I to Model V had similar model random effects estimate and significance. In the full model consisting of the individual-, neighbourhood- and country-level factors, younger women were more likely to have had medicalisation performed compared to women aged 35–49 years. Women who were never married (OR = 1.3; 95% CI: 1.1 to 1.5) were significantly more likely to have medicalisation. Women education increases the odds of FGM medicalisation; women with primary education (OR = 1.4; 95% CI: 1.3 to 1.6), secondary education (OR = 1.8; 95% CI: 1.6 to 2.0) and tertiary education (OR = 2.2; 95% CI: 1.8 to 2.7) have higher odds of FGM medicalisation compared to women with no education. Similarly, the odds of FGM medicalisation increases with the wealth status of the household from which a woman comes from with 29%, 45%- and 75%-times higher odds in the middle, richer and richest household wealth quintiles respectively than those from the poorest households. At the neighbourhood levels, the odds of women in the urban areas (OR = 0.5; 95% CI: 0.4 to 0.7) to have had FGM performed by medical personnel were lower than in rural areas. The odds of having FGM medicalisation increases with community SES compared with women in the high SES neighbourhoods having higher odds of medicalisation compared with those from the least SES neighbourhoods. Women in countries with a high percentage of the rural population have a higher odds (OR = 15.2; 95% CI: 2.0 to 118.1) of medicalisation compared to countries with a low percentage of the rural population.

The percentage total variation attributable to variation between countries is (VPC = 19.5; 95% CI: 3.5 to 30.1) and a median odds ratio (MOR = 3.4; 95% CI: 1.6 to 5.4). Similarly, a high percentage of total variation due to differences between neighbourhoods was observed (VPC = 61.6; 95% CI: 52.1 to 68.0) and a median odds ratio of 6.1 (95% CI: 5.6 to 6.4). In all, the full model (Model V) fitted the data most as it has the lowest deviance value among the five models.

### Discussion

It is apparent from the analyses of data from eleven countries in SSA that FGM performed by healthcare workers had a direct relationship with the level of socioeconomic status irrespective of country of location and place of residence. Specifically, the report of FGM performed by health worker was commonest among women from the highest wealth quintiles compared to those with the poorest wealth quintiles. Similarly, medicalised FGM also had a direct relationship with the level of education.
Although, medicalised FGM was more commonly reported by single women compared to those in marital union, but this observation was not statistically significant. The study also showed that there might be variation in the degree of association between the rate of medicalised
FGM and socioeconomic status across the 11 eleven countries considered in this analysis.

Although FGM is a socio-cultural practice, findings from our analyses suggest that there might be other drivers for the practice among women. High socioeconomic status and education have been largely associated with better access to health information, health-seeking behaviour and quality of healthy living (Chan, Lee, & Low, 2018; Latunji & Akinyemi, 2018). The general belief is that women are vulnerable to harmful traditional practices because of their low social status in the society, poor education and poverty. However, in this study, we observed contrary to the general norm that women whose family were ranked with the highest socioeconomic status and education were not protected from the cultural practice of FGM. While other women sought FGM from traditional practitioners in their communities, women whose family were of high social class might have facilitated this cultural practice during visits to their healthcare practitioners. Generally, skill acquisition to perform FGM is not part of the pre-service training curriculum of any medical professionals in SSA, but some health workers acquire this skill through interaction with their colleagues in their communities that illegally engage in it.

Among the thirteen countries that had data on FGM that were performed by health workers, women from Guinea, Kenya and Nigeria had a relatively high prevalence of 18.2%, 15.1% and 9.1%, respectively. The relatively high proportion of medicalised FGM in these countries are not known. More so that health workers in these countries did not receive any pre-service training on how to perform FGM like other countries in SSA. Though, the government of Nigeria and Kenya criminalised FGM in its entirety in 2016, 2015 and 2011, respectively, these countries do not have national implementation strategy to enforce these laws to eliminate this harmful cultural practice (UN Population Fund (UNFPA) (2018). None of these three countries has successfully prosecuted any healthcare providers that performed FGM (UN Population Fund (UNFPA) (2018). In fact, there was a report of a medical practitioner that challenged the law criminalising FGM in Kenya because she felt that the law is infringing on the fundamental human right of people (Muthini, 2018).

The findings from these analyses have some limitations. The analyses did not have information on reasons why women with high socioeconomic status and education had a higher risk of medicalised FGM than those women from lower or poorest status. Some studies showed that women with high socioeconomic class still prefer their cultural values and would not mind inducing health workers to “safely” perform FGM for their children. The women believed that the performance of FGM by health workers might not be associated with complications such as bleeding and infections. A systematic review in 2017 showed that some health workers clandestinely performed FGM for economic reasons and to protect the right of people in their environment (Doucet et al., 2017). The cross-sectional design of the NDHS data makes it impossible to draw causality between the risk of medicalised FGM as an outcome and the selected explanatory variables. There is also a plausibility of underreporting of FGM in SSA because of the existing laws that had criminalise FGM practice by the traditional healers and health workers in these countries. Notwithstanding, this study has a number of strengths. The study used a large pooled nationally representative datasets from 11 countries to test the hypothesis between the report of medicalised FGM and explanatory variables. We used multilevel analyses to check for the effect of the individual, neighbourhood and country levels with the risk of reporting medicalised FGM, this statistical approach makes the findings generalisable (Uthman et al., 2016 Uthman, Sambala et al., 2018).

In conclusion, medicalised FGM is a common practice among women from a high socioeconomic and educational background in SSA. Medicalisation of FGM is highly prevalent among women of high social class and those residing in rural areas. Medicalised FGM was found to be highest in Guinea, where nearly all women had FGM among which a fifth was medicalised, followed by Nigeria and Kenya, despite the availability of laws banning FGM practice in these countries. We recommend that the government should initiate a culturally sensitive policy that will discourage perpetuation of FGM, particularly by healthcare providers. Future studies should focus on identifying drivers of FGM among the high social class families in the society in SSA. We recommend more study, particularly qualitative research in order to understand the real reason why medical practitioners succumb to pressure to offer FGM services in their localities.

Ethical approval

Ethical approval is not needed, the study used secondary data from the Demography Health Surveys (DHS). The DHS program maintain strict standards for protecting the privacy of respondents. Each country-specific DHS survey protocols are reviewed by the ICF and Institutional Review Board (IRB) in each country to ensure that the survey complies with the regulations for the protection of human subjects and ensures that the survey complies with laws and norms of each country.

Declaration of competing interest

The authors declare that they have no competing interests.

Ethical approval

Ethical approval is not needed, the study used secondary data from cross-sectional surveys.

Data sharing

The data supporting this article is available at: http://dhsprogram.com/data/available-datasets.cfm, which can be downloaded after request from the DHS website.

Contributors

I.O. Morhason-Bello conceptualised and design the study, contributed to the interpretation of findings and writing of initial draft. AFF contributed to the design, methodology, statistical analysis, interpretation of findings and writing of the initial draft. YOK contributed to design of the study, methodology, statistical analysis, interpretation, and writing of the initial draft. OAO contributed to the design and revision of the manuscript. All authors wrote, read and approved the final manuscript.

Funding

This research received no grant from any funding agency in public, commercial or not-for-profit sectors.

Acknowledgement

We are grateful to DHS Program for providing access to the data.

References

Bazi, T. (2017). Female genital mutilation: The role of medical professional organizations. International Urogynaecology Journal, 28(4), 537–541.
Cappa, C., Van Baalen, L., & Leye, E. (2019). The practice of female genital mutilation across the world: Data availability and approaches to measurement. Global Public Health, 1–14.
Chan, C. Q. H., Lee, K. H., & Low, L. L. (2018). A systematic review of health status, health seeking behaviour and healthcare utilisation of low socioeconomic status populations in urban Singapore. International Journal for Equity in Health, 17(11), 39.
Creighton, S. M., Samuel, Z., Otoo-Oyortey, N., & Hodes, D. (2019). Tackling female genital mutilation in the UK. BMJ, 364, 115.
Doucet, M. H., Pallitto, C., & Groeleu, D. (2017). Understanding the motivations of health-care providers in performing female genital mutilation: An integrative review of the literature. Reproductive Health, 14(1), 46.
Farage, M. A., Miller, K. W., Tsegai, G. E., Azuka, C. E., Sobel, J. D., Ledger, et al. (2015). Female genital cutting: Confronting cultural challenges and health complications across the lifespan. Women’s Health, 11(3), 79–94.

Karlsen, S., Mogilnicka, M., Carver, N., & Pantazis, C. (2019). Female genital mutilation: Empirical evidence supports concerns about statistics and safeguarding. BMJ, 364, 1915.

Kimani, S., Echo, T., Kimani, V., Muniu, S., Kamau, J., Kigondi, C., et al. (2018). Female genital mutilation/cutting: Innovative training approach for nurse-midwives in high prevalent settings. International Journal of Gynecology & Obstetrics, 5043512.

Kimani, S., & Shell-Duncan, B. (2018). Medicalized female genital mutilation/cutting: Controversial practices and persistent debates. Current Sexual Health Reports, 19(1), 25–34.

Klein, E., Helzner, E., Shayowitz, M., Kohlhoff, S., & Smith-Norowitz, T. A. (2018). Female genital mutilation: Health consequences and complications—A short literature review. International Journal of Gynecology & Obstetrics, 2018, 7365715–7365721. https://doi.org/10.1155/2018/7365715, 7365715, 2018: 7365715.

Larsen, K., & Merlo, J. (2005). Appropriate assessment of neighborhood effects on individual health: Integrating random and fixed effects in multilevel logistic regression. American Journal of Epidemiology, 161(1), 81–88.

Latuoji, O. O., & Akinyemi, O. O. (2018). Factors influencing health-seeking behaviour among civil servants in Ibadan, Nigeria. Annals of Ibadan Postgraduate Medicine, 16(1), 52–60.

Leye, E., Van Eckert, N., Shamu, S., Echo, T., & Barrett, H. (2019). Debating medicalization of female genital mutilation/cutting (FGM/C): Learning from (policy) experiences across countries. Reproductive Health, 16(1), 158.

McAuley, M., & van den Brook, N. (2019). Challenges in the eradication of female genital mutilation/cutting. International Health, 11(1), 1–4.

Muthini, S. (2018). Legalise female genital mutilation. Daily Nation. says doctor in court. Available from: https://www.nation.co.ke/news/Legalise-female-circumcision–say-doctor-in-court/1066-4267584-1.html Access 5 Feb 2020.

Nabaneh, S., & Muula, A. S. (2019). Female genital mutilation/cutting in Africa: A medicalized approach (FGM/C). African Journal of Urology, 15(1), 1–11.

Obianwu, O., Adetunji, A., & Dirisu, O. (2018). Understanding medicalisation of female genital mutilation/cutting (FGM/C): A qualitative study of parents and health workers in Nigeria. Evidence to end FGM/C: Research to help women thrive. New York: Population Council. Available from: https://www.popcouncil.org/uploads/pdfs/2018R01_UnderstandingMedFGMC-Nigeria.pdf Accessed 4th Feb 2020.

Oduokgb, A. A., Afolabi, B. B., Bello, O. O., & Adegbeju, A. S. (2017). Female genital mutilation/cutting in Africa. Translational Andrology and Urology, 6(2), 138–148.

Omon, S. O., Igberase, G. O., Umoeora, J. O. U., Okogbenin, S. A., Otoide, V. O., & Gharoro, E. P. (2006). Female genital mutilation: Knowledge, attitude and practice among nurses. Journal of the National Medical Association, 98(3), 409–414.

Psyka, A., Psyka, A., Ladunbler, C., Complio, E., Palermo, S., Danuser, H., et al. (2018). [Urological sequelae of female genital mutilation]. Urology, 54(1), 1214–1220.

Serov, G. I. (2013). Medicalization of female genital mutilation/cutting. African Journal of Urology, 19(3), 145–149.

Sigurjonsson, H., & Jordal, M. (2018). Addressing female genital mutilation/cutting (FGM/C) in the era of clitoral reconstruction: Plastic surgery. Current Sexual Health Reports, 19(2), 50–56.

Tu, Y. K., Kellett, M., Clercugh, V., & Gilthorpe, M. S. (2005). Problems of correlations between explanatory variables in multiple regression analyses in the dental literature. British Dental Journal, 199(7), 457–461.

UN Population Fund (UNFPA). (2018). Analysis of legal frameworks on female genital mutilation in selected countries in west Africa. Available from: https://www.refworld.org/docid/5aa0117c4.html Accessed 5 February 2020.

United Nations. (2012). UN general assembly adopts worldwide ban on female genital mutilation. Available from: http://www.un.org/News/Press/docs/2012/ga57人大7365715.pdf accessed 3 Feb 2020.

United Nations. (2018). World urbanization prospects - population division - united nations. 1. Available from: https://population.un.org/wup/Download/ Accessed 22nd Dec 2019.

United Nations Development Programme. (2018). The 2018 global multidimensional poverty index (MPI) | human development reports. Human Development Report, 1, 189.

Uthman, O. A., Ekstrom, A. M., & Moradi, T. T. (2016). Influence of socioeconomic position and gender on current cigarette smoking among people living with HIV in sub-Saharan Africa: Disentangling context from composition. BMC Public Health, 16, 998.

Uthman, O. A., Sambala, E. Z., Adamu, A. A., Ndwandwe, D., Wiyeh, A. B., Okkade, T., et al. (2018). Does it really matter where you live? A multilevel analysis of factors associated with missed opportunities for vaccination in sub-Saharan Africa. Human Vaccines & Immunotherapeutics, 14(10), 2397–2404.

Utz-Billing, I., & Kentenich, H. (2008). Female genital mutilation: An injury, physical and mental harm. Journal of Psychosomatic Obstetrics and Gynaecology, 29(4), 225–229.

World Health Organisation. (2012). Understanding and addressing violence against women: Female genital mutilation. WHO/RHR/12.35. Available from: http://apps.who.int/iris/bitstream/10665/77428/1/WHO_RHR_12.41_eng.pdf Accessed 5 Feb 2020.

Yoder, P. S., Wang, S., & Johansen, E. (2013). Estimates of female genital mutilation/cutting in 27 African countries and Yemen. Studies in Family Planning, 44(2), 189–204.